

We thank Suhai Qian and colleagues for their interest in our investigation of rheumatoid arthritis-associated interstitial lung disease (ILD) risk factors in patients with early rheumatoid arthritis.1 We agree that additional, large prospective studies are needed in this critical rheumatoid arthritis period. Qian and colleagues suggest that findings from our sensitivity analyses cast doubt on the observed association between rheumatoid arthritis disease activity and rheumatoid arthritis-associated ILD, a previously identified ILD risk factor in established rheumatoid arthritis.
Rheumatology
|11th Mar, 2026
|The New England Journal of Medicine
Rheumatology
|11th Mar, 2026
|The New England Journal of Medicine
Rheumatology
|11th Mar, 2026
|The Lancet
Rheumatology
|11th Mar, 2026
|The Lancet
Rheumatology
|11th Mar, 2026
|The Lancet
Rheumatology
|11th Mar, 2026
|The Lancet
Rheumatology
|11th Mar, 2026
|The Lancet